ANIX - NASDAQ
Anixa Biosciences, Inc.
$2.52
-6.7%Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. It has a collaboration agreement with MolGenie GmbH to discover and develop anti-viral drug candidates against COVID-19. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.
At a Glance
Live SnapshotAnixa Biosciences, Inc. Management Team
Dr. Pamela D. Garzone Ph.D.
Chief Development Officer & Chair Breast Cancer Clinical Advisory Board
Dr. Amit Kumar Ph.D.
Chief Executive Officer, Chairman & Co-Chair of CBAB
Compensation
$1,383,037
Mr. Michael J. Catelani CPA, MBA
President, Chief Operating Officer, Chief Financial Officer & Corporate Secretary
Compensation
$713,502
Anixa Biosciences, Inc. Insider Positioning
During the last 12 months, insiders have purchased $754K worth of ANIX shares, with no selling activity reported.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
10.0K
30.40K
0
0.00
+30K
+$30K
6-9 Months
200.0K
584.00K
0
0.00
+584K
+$584K
9-12 Months
45.0K
139.20K
0
0.00
+139K
+$139K
Top Buyers
Kumar Amit
Officer: Chief Executive Officer
$644K
Titterton Lewis H Jr
Director
$62K
Baskies Arnold M
Director
$47K
Top Sellers
No selling activity
Insider Activity Analysis
Net Insider Sentiment
Strong bullish signal with $754K net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Buy/Sell Ratio
Perfect buy/sell ratio. Only buying activity with zero selling—the most bullish possible insider signal.
Insider Participation
3 insider buyers vs. 0 sellers. Broad-based buying across management team suggests widespread confidence.
Insider Activity Insight
Compelling insider conviction: The combination of strong buy/sell ratio and multiple buyers suggests insiders see attractive risk/reward. Consider this alongside fundamental analysis for confirmation.
SEC Filings
ANIX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | January 28, 2026 | January 28, 2026 | 2026 | |
DEF 14A DEF 14A 2024 N/A | February 06, 2025 | October 31, 2024 | 2024 | |
DEF 14A DEF 14A 2024 N/A | February 08, 2024 | February 08, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | January 27, 2023 | January 27, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | January 28, 2022 | January 28, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 09, 2021 | April 09, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | July 02, 2020 | July 02, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | September 12, 2019 | September 12, 2019 | 2019 | |
DEF 14A DEF 14A 2018 N/A | August 17, 2018 | August 17, 2018 | 2018 | |
DEF 14A DEF 14A 2018 N/A | February 12, 2018 | February 12, 2018 | 2018 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.